Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.64 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668088 | 0.81 | EGFR (0.78) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL4292679 | 0.80 | EGFR (0.84) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3667850 | 0.79 | EGFR (0.82) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3670894 | 0.79 | EGFR (1.00) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3669992 | 0.78 | EGFR (1.00) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3667999 | 0.77 | EGFR (0.88) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3668156 | 0.76 | EGFR (1.00) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL18041924 | 0.76 | EGFR (0.69) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3671866 | 0.74 | EGFR (0.66) | EGFRMAP4K4ERBB2MAPK9CSNK1D | |
| SCHEMBL3670036 | 0.71 | MAPK14 (0.64) | EGFRMAP4K4ERBB2MAPK9CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | EGFR 876/4885MAP4K4 51/4885ERBB2 345/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | EGFR 876/4885MAP4K4 51/4885ERBB2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.